An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model
Chenwei Wang(Baylor College of Medicine), Lin Chen(Hong Kong Polytechnic University), Xiaolong Liang(Peking University), Zibing Wang(Huazhong University of Science and Technology), Hongle Li(Shanghai Jiao Tong University), Lihong Huang(Guangzhou Medical University), Zhihong Xu(Guangzhou Medical University), Lei Chen(Zhuzhou Central Hospital), Gang� Li(Brown Foundation), Hai Hu(General Hospital of Guangzhou Military Command), Jingyao Li(Shanghai University), Danyi Du(Southern Medical University), Qian Zhao(Nanjing Agricultural University), Xiaoling Wang(Zhejiang University-University of Edinburgh Institute), Hua You(Third People's Hospital of Hangzhou), Jiewen Chen(Sun Yat-sen University), Chengjie Xiong(Guangzhou Institutes of Biomedicine and Health), Bing Wu(China Agricultural University)
Cited by 6
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
|Alzheimer s Research & Therapy|2010|562
Symptom onset in autosomal dominant Alzheimer disease
|Neurology|2014|515